Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emblem Corp EMMBF

Healthcare Biotechnology Cannabis
"Emblem Corp is a licensed producer of medical cannabis. It is intended to cultivate and cure cannabis for medicinal use. The group operates in the business segment of production and sale of medical cannabis."


OTCPK:EMMBF - Post by User

Emblem Corp > Emblem Positioned to be Disruptive in Medical Cannabis
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(32)
•••
Comment by cresscoon Oct 11, 2017 3:59pm
84 Views
Post# 26801035

RE:RE:Emblem Positioned to be Disruptive in Medical Cannabis

RE:RE:Emblem Positioned to be Disruptive in Medical Cannabis
deminimis wrote: They expect to begin selling the pain release medication by fall 2018? Damn, that is much sooner than I expected. Glad to see they are actually trying to promote the stock again.


I thought the same thing, I guess pain studies aren't as time consuming. I also like this quote from the last news release: "......We are also looking forward to further collaborations with Canntab to bring other groundbreaking cannabis-based advanced dosage forms to the market." Regards
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested